Bibliographical noteFunding Information:
Please note: This study was supported by Genentech, Inc . and BioInvent International AB . Dr. Lehrer-Graiwer is an employee of and holds stock in Global Blood Therapeutics. Dr. Singh was supported by a grant from the National Heart, Lung, and Blood Institute (5T32 HL076136). Dr. Korsgren was employed by BioInvent at the time of the study. Drs. Baruch and van Bruggen are employees of Genentech/Roche. Drs. Fredrickson and Tang are employees and stockholders of Genentech/Roche. Dr. Frendeus is an employee of BioInvent. Dr. Rudd is partly supported by the Cambridge NIHR Biomedical Research Centre . Dr. Ballantyne has received grant support and consulting fees from Genentech / Roche . Dr. Ghoshhajra has received consulting fees from Siemens. Dr. Rosenson has served on advisory boards for and has received grant support (institution) from F. Hoffman La Roche. Dr. Koren has received research grants from Roche . Dr. Roth has received consulting fees from Amgen, Sanofi, and Regeneron. Dr. Duprez has received research grants from Amgen , Sanofi , Regeneron , and Pfizer ; and has served on advisory boards for AstraZeneca and Novartis. Dr. Fayad has received grant support from Genentech / Roche . Dr. Tawakol has received grant support from Genentech / Roche ; and has received consulting fees from Genentech/Roche and BioInvent. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Lehrer-Graiwer and Singh contributed equally to this study and are co-first authors.